SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Astrazeneca to List All US Securities On Nasdaq Starting September 25

AstraZeneca (NYSE: AZN) today announced that it will be transferring the listing of its American Depositary Receipts (ADRs) and its US-listed debt securities from the New York Stock Exchange (NYSE) to the Nasdaq Global Select Market (Nasdaq) and Nasdaq Bond Exchange respectively.

· 09/10/2020 05:40
AstraZeneca (NYSE:AZN) today announced that it will be transferring the listing of its American Depositary Receipts (ADRs) and its US-listed debt securities from the New York Stock Exchange (NYSE) to the Nasdaq Global Select Market (Nasdaq) and Nasdaq Bond Exchange respectively. The transfers will be effective after market close on Thursday 24 September 2020.   AstraZeneca ADRs and US-listed debt securities are expected to commence trading on Nasdaq from Friday 25 September 2020. The ADRs will continue to be listed under the ticker symbol "AZN". The Company's primary listing in the UK on the London Stock Exchange and in Sweden on Nasdaq Stockholm are unaffected by the move.   Marc Dunoyer, Executive Director and Chief Financial Officer, said: "The change of stock exchange in the US will reduce overall listing cost for our equity and debt securities. Further, as a global science-led, patient-focused biopharmaceutical company, dedicated to pushing the boundaries of science to deliver life-changing medicines, we are excited to be joining many of the world's largest and most innovative companies on Nasdaq."   Thomas Kudsk Larsen, Head of Investor Relations, said: "The move to Nasdaq for US listing will provide access to stock-market indices for AstraZeneca's ADR, which is of increasing importance due to the expanded use of exchange-traded funds as well as index and passive investment strategies. We continuously focus on improving conditions for shareholders and potential new investors and the move to Nasdaq is a logical next step."